

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. DO NOT EXCEED FIVE PAGES.

NAME: Tina Mayer

eRA COMMONS USER NAME (credential, e.g., agency login): mayertm

POSITION TITLE: Associate Professor of Medicine

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Cornell University, 172 Goldwin Smith Hall, Ithaca, NY	B.A.	5/1999	Biology
Weill Medical College of Cornell University, NY, NY	M.D.	5/2003	Medicine
Tufts Medical Center, Boston, MA	N/A	6/2006	Internal Medicine Internship-Residency
Yale Medical School/Yale, New Haven, CT	N/A	6/2009	Medical Oncology and Hematology Fellowship

Personal Statement

Since joining Rutgers CINJ/RWJMS in March 2009 as a medical oncologist, I have excelled in teaching, clinical research and providing clinical care. My clinical activity and scholarship are focused in the area of genitourinary (GU) oncology. I manage a busy clinical practice in GU oncology, and regularly engage with my colleagues in Radiation Oncology, Urology, Radiology, Pathology as well as other disciplines as needed in order to provide the best clinical care to my patients. My peers recognize me locally and regionally as expert in genitourinary malignancies. As a clinical researcher who has enthusiastically recruited many patients to clinical trials, I play a vital role in the clinical research program in the GU Oncology group. I have functioned as site-Principal Investigator on numerous trials, bringing novel and groundbreaking treatment options to our patients and have extensive experience in running and enrolling patients into clinical trials.

My passion for teaching has led me to serve as the Program Director for the Hematology/Oncology Fellowship Program. In this role since July 2022, as well as my prior role at Associate Program Director, I have successfully driven positive changes to strengthen the fellowship program including enhancements to the clinical training, curriculum and conference series. Given my strong interest in global health, I established a global oncology program within the fellowship in 2018. As director of this program, I have mentored fellows in projects related to cancer care in sub-Saharan Africa. I have also facilitated opportunities for fellows to have an immersive experience in Botswana, allowing them exposure to the complexities of cancer care and prevention in Africa. Efforts included assisting in the development of cancer guides guidelines for the Botswana Ministry of Health, delivery of a virtual lecture series to faculty and staff in Botswana which addressed oncologic emergencies, collaborating on the Cancer Kitso program teaching oncology care to faculty and staff in Botswana.

My experience in the areas of clinical trials, medical education, and global oncology, provides a valuable skillset in the development of clinical programs, education and training at Rutgers Cancer Institute of New Jersey.

Positions and Employment

2020 – present Department of Medicine, Medical Oncology, Rutgers, Cancer Institute of New Jersey,
Associate Professor of Medicine

2013- 2020 Department of Medicine, Medical Oncology, Rutgers, Cancer Institute of New Jersey,
Assistant Professor of Medicine

2009-2013 Assistant Professor of Medicine, Department of Medicine, Medical Oncology, University
of Medicine and Dentistry of New Jersey, The Cancer Institute of New Jersey, New Brunswick, NJ

Board Certification: ABIM board certified in Internal Medicine, 2006
 ABIM board certified in Hematology and Oncology, 2009

Other Experience and Professional Memberships

Name of Organization: Rutgers Cancer Institute of New Jersey
Member or other Position: Chair, Barnabas Oncology Service Line GME Committee, Chair
Inclusive dates: 2022 to present

Name of Organization: Rutgers Robert Wood Johnson Medical School
Member or other Position: Program Director, Hematology/Oncology Fellowship
Inclusive dates: 2022 to present

Name of Organization: Rutgers RWJMS Faculty Engagement Task Force
Member or other Position: Value in Education Committee Member
Inclusive dates: 2020 to 2022

Name of Organization: Rutgers Global Health Institute
Member or other Position: Core Faculty Member
Inclusive dates: 2019 to present

Name of Organization: Rutgers Global Health Institute
Member or other Position: Membership Committee
Inclusive dates: 2019 to present

Name of Organization: Robert Wood Johnson University Hospital New Brunswick
Member or other Position: Cancer Committee Member
Inclusive dates: 2017 to present

Name of Organization: Rutgers Robert Wood Johnson Medical School
Member or other Position: Associate Program Director, Hematology/Oncology Fellowship
Inclusive dates: 2016 to present

Name of Organization: Rutgers Cancer Institute of New Jersey
Member or other Position: Genitourinary Study Group, Clinical Investigations and Therapeutics Program
Member
Inclusive dates: 2009 to present

Name of Organization: Rutgers Cancer Institute of New Jersey
Member or other Position: Scientific Review Board
Inclusive dates: 2009 to present

Name of Organization: Rutgers Cancer Institute of New Jersey
Member or other Position: Human Research Oversight Committee

Inclusive dates: 2010 to 2015

Name of Organization: Rutgers Robert Wood Johnson Medical School
Member or other Position: Patient Centered Medicine III Course facilitator
Inclusive dates: 2014 to 2015, 2019 - present

Name of Organization: Rutgers Robert Wood Johnson Medical School
Member or other Position: Course director, Clinical Oncology Elective for Internal Medicine residents
Inclusive dates: 2010 to present

Name of Organization: Hoosier Cancer Research Network GU Clinical Trial Working Group
Member or other Position: Member
Inclusive dates: 2017 to present

Name of Organization: BIG TEN Cancer Research Consortium
Member or other Position: Member
Inclusive dates: 2017 to present

Name of Organization American Society of Clinical Oncology
Member or other Position: Member
Inclusive dates: July 2006 – present

Name of Organization: Rutgers Robert Wood Johnson Medical School
Member or other Position: Course director, Clinical Oncology Elective for medical students
Inclusive dates: 2016 to 2018

Name of Organization: Rutgers Cancer Institute of New Jersey
Member or other Position: Clinical Faculty Satisfaction Working Group Leader
Inclusive dates: 2016

Name of Organization: Rutgers Robert Wood Johnson Medical School
Member or other Position: Patient Centered Medicine I/II Course facilitator
Inclusive dates: 2010 to 2016

Honors

2020 Young Medical Education Innovator Award, Institute for Excellence in Education, Rutgers Robert Wood Johnson Medical School
2019 Rutgers RBHS Academic Leadership Program, Awarded by Rutgers University, program September 2019 – May 2020
2019 OASIS Leadership & Professional Development Program, Awarded by Rutgers University, program January 2019 – May 2019
2002 Ida S. Scudder Scholarship (chosen to represent the medical college for a 4 week medical elective program at Christian Medical College in Vellore, India)
1999 Phi Beta Kappa Honor Society
1999 Golden Key National Honor Society

C. Contribution to Science

I am an active clinical investigator, dedicated to advancement of cancer therapies through opening of clinical trials, and enrolling patients into trials with novel therapies or combinations of therapies. I regularly engage in academic projects related to advancement of field of genitourinary oncology. I am pursuing projects and educational initiatives in arena of global oncology, specifically sub-Saharan Africa.
Selected publications:

Kim IY, Mitrofanova A, Panja S, Sterling J, Srivastava A, Kim J, Kim S, Singer E, Jang T, Ghodoussipour S, Saraiya B, **Mayer T**, Sabaawy H, Yuh B, Byun S, Kim WJ, Horie S. Genomic analysis and long-term outcomes of a phase I clinical trial on cytoreductive prostatectomy. *Prostate International*, 10(2): 75-79, 2022.

Patel H, Kim S, Srivastava A, Shinder B, Sterling J, Saraiya B, **Mayer T**, Ghodoussipour S, Jang T, Singer E. Factors associated with palliative intervention utilization for metastatic renal cell carcinoma. *Clin Genitourin Cancer*, Jan 7;S1558, 2022.

Autio KA, Antonarakis ES, **Mayer TM**, Shevrin DH, Stein MN, Vaishampayan UN, Morris MJ, Slovin SF, Heath EI, Tagawa ST, Rathkopf DE, Milowsky MI, Harrison MR, Beer TM, Balar AV, Armstrong AJ, George DJ, Paller CJ, Apollo A, Danila DC, Graff JN, Nordquist L, Dayan Cohn ES, Tse K, Schreiber NA. Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy. *Eur Urol Open Sci*, 34:70-78, 2021.

Bitting R, Healy P, George D, Anand M, Kim S, **Mayer T**, Winters C, Riggan C, Rasmussen J, Wilder R, Stein MS, Frizzell B, Harrison M, Zhang T, Lee W, Wu Y, Koontz B, Armstrong A. Phase II trial of enzalutamide and androgen deprivation therapy with salvage radiation in men with high-risk prostate-specific antigen recurrent prostate cancer: the STREAM trial. *European Urology Oncology*, 4(6): 948-954, 2021

Shiuan E, Reddy A, Dudzinski S, Lim A, Sugiura A, Hongo R, Young K, Liu XD, Smith C, O'Neal J, Dahlman K, McAlister R, Chen B, Ruma K, Roscoe N, Bender J, Ward J, Kim JY, Vaupel C, Bordeaux J, Ganesan S, **Mayer T**, Riedlinger G, Vincent B, Davis N, Haake S, Rathmell J, Jonasch E, Rini B, Rathmell W, Beckermann K. Clinical features and multiplatform molecular analysis assist in understanding patient response to anti-PD-1/PD-L1 in renal cell carcinoma. *Cancers*, 13(6): 1475, 2021.

Srivastava A, Rivera-Núñez Z, Kim S, Sterling J, Farber N, Radadia K, Patel H, Modi P, Goyal S, Parikh R, **Mayer T**, Saraiya B, Sadimin E, Weiss R, Kim I, Elsamra S, Jang T, Singer E. Impact of pathologic lymph node–positive renal cell carcinoma on survival in patients without metastasis: Evidence in support of expanding the definition of stage IV kidney cancer. *Cancer*, 126; 2991-3001, 2020

Li S, Vuylsteke P, Qureshi S, Antony R, Wilson K, Moumakwa R, Marlink R, Lebelonyane R, Gaolathe T, **Mayer T**, Shah M, Popli P, Chandar A, Kaur S, Ralefala T. Development and implementation of a case-based virtual training program for oncologic emergencies in Botswana. Oral presentation at 9th Annual Symposium on Global Cancer Research, March 10, 2021, Washington DC (virtual).

Chandar A, Kaur S, Toppmeyer D, Ralefala T, Strair R, Philipp C, Marlink R, Antony R, DiGiacobbe M, Lebelonyane R, Gaolathe T, **Mayer M**. Building international partnerships to improve global oncological care: Perspectives from Rutgers-CINJ Global Oncology Fellowship Program. 2019 ASCO Quality of Care Symposium.

Popli P, Shah M, Ralefala T, Toppmeyer D, Strair R, Lebelonyane R, Mompe A, Gaolathe T, Antony R, Marlink R, **Mayer M**. Reducing Oncologic Disparities by Standardizing Cancer Care. 8th Annual Symposium on Global Cancer Research. ASGCR 2020.

D. Additional Information: Research Support and/or Scholastic Performance

- ECLIPSE: A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
 - Principal Investigator: Tina Mayer (site PI)
 - Status: Open to accrual

- EA8191 Phase III Study of Local or Systemic Therapy INTensification Directed by PET in Prostate Cancer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE)
 - Principal Investigator: Tina Mayer (site PI)
 - Status: Open to accrual
- NCI/CTEP #10191: A Phase 2 Study of M6620 in Combination with Carboplatin compared with Docetaxel in Combination with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
 - Principal Investigator: Tina Mayer (site PI)
 - Status: Closed to accrual
- HCRN GU16-287: Randomized Phase 2 Trial of Gemcitabine + Carboplatin + Nivolumab versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-Ineligible Patients with Metastatic Urothelial Cancer.
 - Principal Investigator: Tina Mayer (site PI)
 - Status: Closed to accrual
 -
- BTCRC-GU15-023: Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients with Urothelial Cancer (T2-4 N0-2 M0) of the Bladder.
 - Principal Investigator: Tina Mayer (site PI)
 - Status: Closed to accrual
 -
- KEYNOTE 365: Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
 - Principal Investigator: Tina Mayer (site PI)
 - Status: Open to accrual
 -
- SWOG S0931: EVEREST: EVERolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
 - Principal Investigator: Tina Mayer (site PI)
 - Status: Closed to accrual
 -
- SP005: A randomized, double blind, multicenter, parallel-group, phase III study to evaluate efficacy and safety of DCVAC/PCa versus placebo in men with metastatic castration resistant prostate cancer eligible for 1st line chemotherapy
 - Principal Investigator: Tina Mayer (site PI)
 - Status: Closed to accrual
 -
- c11-092: A Phase II, Randomized, Three-Arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients with Prostate Cancer with a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
 - Principal Investigator: Tina Mayer (site PI)
 - Status: Closed to accrual
 -
- SWOG S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy +TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostrate Cancer
 - Principal Investigator: Tina Mayer (site PI)
 - Status: Closed to accrual
 -
- A randomized, double-blind, controlled phase IIb study of the safety and efficacy of ICT-107 in newly diagnosed patients with glioblastoma multiforme following resection and chemoradiation
 - Principal Investigator: Tina Mayer (site PI)
 - Status: Closed to accrual
 -
- ECOG 2809: Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
 - Principal Investigator: Tina Mayer (site PI)
 - Status: Closed to accrual

-
- Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men with Prostate Cancer: A Randomized, Double-Blind Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-Specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer: Phase II
 - Principal Investigator: Tina Mayer (site PI)
 - Status: Closed to accrual
-
- Randomized Phase II trial of short-course androgen deprivation therapy +/- Avastin for PSA recurrence of prostate cancer after definitive local therapy
 - Principal Investigator: Tina Mayer (site PI)
 - Status: Closed to accrual
-
- A Phase II Study of Single-Agent Tesetaxel in Chemotherapy-Naive Patients Who Have Progressive, Castration-Resistant Prostate Cancer
 - Principal Investigator: Tina Mayer (site PI)
 - Status: Closed to accrual
-
- 212082-PCR-3001: An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy
 - Principal Investigator: Tina Mayer (site PI)
 - Status: Closed to accrual